Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

BRCA1/2 mutation carriers vs the general breast cancer population (N = 799,986): 21-gene assay-based molecular characterization.

Breast cancer research and treatment - 1 Jul 2024

Yerushalmi Rinat, Pomerantz Adi, Lewin Ron, Paluch-Shimon Shani, Soussan-Gutman Lior, Baehner Frederick L, Voet Hillary, Bareket-Samish Avital, Kedar Inbal, Goldberg Yael, Peretz-Yablonski Tamar, Kadouri Luna

Abstract excerpt

PURPOSE: We compared 21-gene recurrence score (RS) distribution and expression of the single-gene/gene groups within this assay between BC patients with pathogenic variants (PV) in BRCA1/2 vs the general 21-gene-tested BC population. METHODS: This retrospective study included consecutive 21-gene-tested female ER + HER2-negative BC patients with germline PVs in BRCA1/2. RS/gene expression data were compared to a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Biomarkers, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to BRCA1 Protein

Share to BRCA2 Protein

Share to Breast Neoplasms

Share to Genetic Predisposition to Disease

Share to Germ-Line Mutation

Share to Heterozygote

Source

Open in PubMed Open full text

Identifiers

PMID: 38568368
DOI: 10.1007/s10549-024-07271-4
PMCID: PMC11182787

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

BRCA1/2 mutation carriers vs the general breast cancer population (N = 799,986): 21-gene assay-based molecular characterization.PMID 38568368Read ↗

Utilization and impact of 21-gene recurrence score assay for breast cancer in clinical practice across the United States: lessons learned from the 2010 to 2012 National Cancer Data Base analysis.Semantic proximity Read ↗

PreciseBreast is prognostic for breast cancer recurrence in a 21-gene assay managed cohortSemantic proximity Read ↗

Utilization and Outcomes of the 21-Gene Recurrence Score in pN2 Breast Cancer PatientsSemantic proximity Read ↗

21-Gene Recurrence Score Assay As a Predictor of Adjuvant Chemotherapy Administration for Early-Stage Breast Cancer: An Analysis of Use, Therapeutic Implications, and Disparity Profile.Semantic proximity Read ↗

Prospective Validation of a 21-Gene Expression Assay in Breast CancerSemantic proximity Read ↗

Application of a 21-Gene Recurrence Score in a Swiss Single Center Breast Cancer Population. A Comparative Analysis of Treatment Administration before and after TAILORxSemantic proximity Read ↗

21-Gene recurrence score decreases receipt of chemotherapy in ER+ early-stage breast cancer: an analysis of the NCDB 2010-2013.Semantic proximity Read ↗

Twenty-one-gene recurrence score assay in BRCA-associated versus sporadic breast cancers: Differences based on germline mutation status.Semantic proximity Read ↗

The 21-Gene Recurrence Score in Clinically High Risk Lobular and Ductal Breast Cancer: A National Cancer Database StudySemantic proximity Read ↗

Breast medical oncologists' use of standard prognostic factors to predict a 21-gene recurrence score.Semantic proximity Read ↗

Comparing an AI test to a 21-gene assay for premenopausal node-positive HR+/HER2-breast cancerSemantic proximity Read ↗

Impact of Different Modules of 21-Gene Assay in Early Breast Cancer PatientsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.